Last updated: September 8, 2026
Entyvio Pen is Takeda’s subcutaneous vedolizumab delivery product for adult ulcerative colitis and Crohn’s disease. The pen extends the commercial life of Entyvio beyond its intravenous formulation by shifting maintenance treatment toward at-home administration. Takeda does not separately disclose Entyvio Pen revenue, so financial analysis relies on total Entyvio sales, formulation uptake, label expansion, and biologic-exclusivity timing.
The principal commercial risks are U.S. biologic competition after the reference-product exclusivity period, payer pressure on high-cost inflammatory bowel disease therapies, and substitution between intravenous Entyvio and the subcutaneous pen. The pen’s main defenses are patient convenience, established physician familiarity with Entyvio, formulation and device-related intellectual property, and the difficulty of developing a clinically interchangeable vedolizumab product.
What is Entyvio Pen and how does it differ from intravenous Entyvio?
Entyvio Pen contains vedolizumab, a monoclonal antibody that selectively binds the alpha4beta7 integrin and inhibits gut-selective lymphocyte trafficking. Takeda markets Entyvio in two maintenance-delivery formats:
| Attribute |
Entyvio intravenous |
Entyvio Pen or prefilled subcutaneous injection |
| Active ingredient |
Vedolizumab |
Vedolizumab |
| Dose |
300 mg IV infusion |
108 mg subcutaneous injection |
| Primary use |
Induction and maintenance |
Maintenance after IV induction |
| Administration |
Health-care setting |
Patient or caregiver administration |
| Typical maintenance schedule |
IV at labeled intervals |
Every two weeks in the U.S. label |
| Main commercial advantage |
Established clinical pathway |
Convenience and reduced infusion burden |
| Main commercial risk |
Infusion-center dependence |
Device, adherence and training requirements |
The FDA approved subcutaneous Entyvio in 2019 as a prefilled syringe maintenance option and approved the Entyvio Pen presentation in 2023. The U.S. label requires patients to receive at least two IV doses before beginning subcutaneous maintenance therapy. The pen is therefore primarily a lifecycle-management product rather than a replacement for IV induction therapy. (FDA, 2023a; FDA, 2023b)
What patient segment is most relevant to Entyvio Pen?
The pen is most relevant to adults who have responded to IV induction and prefer home treatment. It is also positioned for patients who face infusion-center access problems, work-related scheduling constraints, travel requirements, or a preference for self-administration.
The commercial opportunity is narrower than total Entyvio use because:
- IV induction remains necessary under the U.S. label.
- Some patients and clinicians prefer supervised infusion.
- Payers may impose separate coverage rules for provider-administered and pharmacy-benefit products.
- A portion of existing subcutaneous users may use the prefilled syringe rather than the pen.
- Patients with adherence or injection-training concerns may remain on IV therapy.
How has Entyvio revenue developed?
Takeda reports Entyvio as a global product franchise and does not provide a separate revenue line for the pen. Public financial reporting therefore cannot isolate pen sales, prescription volume, gross-to-net deductions, or the percentage of Entyvio patients using subcutaneous administration.
| Financial indicator |
Publicly disclosed position |
| Product company |
Takeda Pharmaceutical |
| Core product |
Entyvio, vedolizumab |
| Commercial launch |
U.S. IV launch in 2014 |
| Global revenue scale |
Approximately ¥300 billion-plus annually in recent Takeda reporting periods |
| Pen-specific revenue |
Not separately disclosed |
| Revenue driver |
Continued IBD penetration, maintenance duration, geographic expansion and formulation conversion |
| Main maturity risk |
Biologic competition and payer pressure after reference-product exclusivity |
Takeda has identified Entyvio as one of its key growth products. Revenue expanded materially after launch as the drug gained share in ulcerative colitis and Crohn’s disease, received broader geographic access, and accumulated long-term maintenance patients. Growth has moderated as the product has matured and as competing biologics, targeted small molecules and biosimilar programs have increased pressure across inflammatory bowel disease.
The pen can support revenue durability in three ways:
- It can reduce switching to competing self-administered therapies.
- It can move appropriate patients from infusion-center treatment to home maintenance.
- It can create a differentiated presentation when price competition affects the underlying molecule.
The pen can also reduce the apparent growth rate of the IV product if patients convert from infusion to subcutaneous treatment. That conversion is commercially favorable only if Takeda retains the patient and preserves net pricing.
What is the financial trajectory for Entyvio Pen?
The near-term trajectory is likely to depend more on formulation adoption than on new indications. Entyvio already has established approvals in ulcerative colitis and Crohn’s disease. The pen’s financial contribution should therefore be evaluated through five indicators:
| Indicator |
Commercial interpretation |
| Subcutaneous prescription share |
Measures conversion from IV maintenance and competitive retention |
| Net price relative to IV Entyvio |
Determines whether convenience produces incremental value or only channel substitution |
| New-start share |
Shows whether physicians prescribe Entyvio with home maintenance in mind |
| Payer coverage |
Determines pharmacy access and prior-authorization friction |
| Patient persistence |
Indicates whether the pen improves treatment continuity |
The strongest financial scenario is a gradual migration of stable IV patients to the pen combined with continued new patient starts. The weaker scenario is rapid price discounting, limited pharmacy-benefit coverage, and conversion of existing IV patients without meaningful improvement in net revenue.
Takeda’s annual reporting does not provide enough detail to calculate pen-specific margins or a standalone return on investment. The relevant financial exposure is the entire Entyvio franchise, which is large enough that even modest erosion from biosimilars or competing therapies could materially affect Takeda’s growth-product portfolio.
When does Entyvio lose U.S. biologic exclusivity?
Entyvio was first licensed by the FDA on May 20, 2014. Under the Biologics Price Competition and Innovation Act, the reference product receives 12 years of data exclusivity from first licensure. The statutory exclusivity period therefore reaches its principal endpoint in May 2026, subject to FDA regulatory treatment and any applicable patent or litigation constraints. (FDA, 2024a)
The key U.S. timeline is:
| Event |
Date or status |
| FDA approval of IV Entyvio |
May 20, 2014 |
| FDA approval of subcutaneous Entyvio |
2019 |
| FDA approval of Entyvio Pen presentation |
2023 |
| Earliest general biosimilar application filing window |
Four years after first licensure |
| Reference-product data exclusivity |
Twelve years after first licensure |
| Principal exclusivity endpoint |
May 2026 |
| Biosimilar approval possibility |
Dependent on application, patent, interchangeability and litigation outcomes |
Approval of the pen does not reset the 12-year reference-product exclusivity period. A new device presentation generally does not create a new biologic reference-product exclusivity term for the original active ingredient.
What patents protect Entyvio and Entyvio Pen?
Entyvio’s protection is likely to involve several patent categories rather than one patent covering the pen as a whole:
- Antibody and biologic composition patents.
- Antigen-binding and sequence-related patents.
- Methods of treating ulcerative colitis and Crohn’s disease.
- Dosing and maintenance-treatment claims.
- Subcutaneous formulations and concentration claims.
- Device or container-closure patents covering the pen presentation.
- Manufacturing and purification processes.
Patent protection must be evaluated separately from FDA exclusivity. A biosimilar applicant can file after the statutory filing window, but commercial launch may depend on patent certification, litigation, settlement terms and any injunction or launch restriction.
The U.S. Orange Book is not the principal listing system for Entyvio because Entyvio is a biologic. Biologic reference products are associated with the FDA Purple Book rather than the Orange Book. As a result, Entyvio does not present the same Orange Book Paragraph IV framework used for conventional small-molecule drugs. (FDA, 2024b)
Are there Paragraph IV challenges to Entyvio?
No conventional Orange Book Paragraph IV pathway applies to Entyvio. Biosimilar applicants use the BPCIA information-exchange and patent-resolution process, commonly called the patent dance, rather than submitting an ANDA with Paragraph IV certifications.
A biosimilar company may challenge patents through the BPCIA process, declaratory litigation, inter partes review or other district-court proceedings. The absence of an Orange Book Paragraph IV listing does not mean the reference product lacks patent risk. It changes the procedural route.
What biosimilar risks exist for Entyvio?
Vedolizumab is a complex monoclonal antibody, so biosimilar development requires analytical comparability, pharmacokinetic and immunogenicity evidence, manufacturing capacity, and regulatory interaction with FDA. A biosimilar does not need to duplicate every commercial presentation to create price pressure.
The risk profile differs by product type:
| Competitor type |
Risk to Entyvio |
| IV vedolizumab biosimilar |
Direct price and hospital or infusion-channel pressure |
| Subcutaneous vedolizumab biosimilar |
Direct risk to Entyvio Pen and syringe retention |
| Anti-TNF biosimilars |
Indirect payer and formulary pressure |
| Ustekinumab biosimilars |
Competitive pressure in Crohn’s disease and ulcerative colitis |
| Oral JAK inhibitors |
Convenience and rapid-onset competition, with differentiated safety considerations |
| IL-23 inhibitors |
Increasing competition for IBD treatment sequencing |
The first commercial biosimilar entrant may target the IV formulation because it has a simpler established administration pathway. A later subcutaneous competitor could have greater impact on the pen, particularly if it obtains pharmacy-benefit coverage and interchangeable status.
What regulatory advantages does Entyvio Pen have?
The pen benefits from the existing Entyvio clinical and regulatory record. Takeda does not need to establish a new mechanism of action or build an entirely new disease franchise. The principal regulatory work concerns the subcutaneous formulation, delivery device, administration instructions, safety profile and human-factors validation.
The pen’s regulatory advantages include:
- A known active ingredient.
- Existing approvals in two major IBD indications.
- Established immunogenicity and safety data.
- An existing prescriber base.
- A maintenance-use position after IV induction.
The main regulatory limitation is that the U.S. treatment pathway does not make the pen a complete replacement for IV induction. That limits the total addressable patient pool for pen-only treatment.
Which companies challenge Entyvio commercially?
Entyvio competes in a crowded IBD market. The main competitive groups are:
- AbbVie’s Humira and Rinvoq.
- Johnson & Johnson’s Stelara and Tremfya.
- Eli Lilly’s Taltz.
- Janssen and other developers of IL-23 and IL-12/23 therapies.
- Pfizer’s Xeljanz.
- Biosimilar manufacturers developing infliximab, adalimumab and ustekinumab products.
- Future vedolizumab biosimilar manufacturers.
Entyvio’s differentiation is gut-selective mechanism, established efficacy, and an expanding self-administered maintenance option. Its limitations include slower onset than some small-molecule therapies, the requirement for IV induction, and the high cost of biologic treatment.
How strong is the Entyvio Pen patent estate?
The patent estate is commercially meaningful but not equivalent to a new molecule patent estate. The underlying biologic’s protection is approaching the post-launch maturity phase. The pen can add formulation, device and method-of-use barriers, but those claims may be narrower and more vulnerable than broad composition claims.
Patent strength is highest where claims are:
- Specific to vedolizumab sequence or binding properties.
- Supported by detailed formulation data.
- Directed to a validated administration regimen.
- Linked to a device configuration that competitors cannot easily design around.
- Supported by manufacturing complexity that creates practical rather than purely legal barriers.
Patent strength is weaker where protection depends on broad functional language, routine device design, or dosing claims that overlap with the established label and prior art.
What generic or biosimilar launch scenarios exist?
Early launch after exclusivity
A biosimilar applicant launches soon after the May 2026 reference-product exclusivity endpoint, subject to patent resolution. Takeda responds with contracting, patient-support programs, and aggressive conversion of patients to the pen.
IV-first erosion
Biosimilar competition begins with IV vedolizumab. Infusion providers and payers adopt the lower-cost product, while Takeda protects the pen through home-use convenience and formulation differentiation.
Subcutaneous direct competition
A competing subcutaneous vedolizumab product reaches the market. This is the most direct threat to Entyvio Pen because it attacks the same delivery channel and patient segment.
Delayed competition
Patent litigation, manufacturing constraints, regulatory review or settlement terms delay commercial entry. Takeda gains additional time to expand pen penetration and negotiate long-term payer contracts.
What litigation and settlement issues affect Entyvio?
The principal legal issues are expected to involve BPCIA patent exchanges, patent-validity challenges, infringement claims, formulation patents, device patents and launch timing. Public commercial analysis should distinguish three dates:
- FDA approval of a biosimilar.
- Resolution of patent litigation or settlement.
- Actual commercial launch.
Those dates can differ substantially. A biosimilar may be approved but remain off the market because of a patent settlement or agreed launch date. Conversely, a company may launch at risk before all patent disputes are resolved.
No Orange Book-based Paragraph IV litigation framework applies to Entyvio. Any settlement analysis must therefore focus on BPCIA litigation, district-court records, patent-office proceedings and announced launch provisions.
What is the geographic coverage of Entyvio Pen?
Takeda has pursued subcutaneous vedolizumab approvals across major regulated markets, but the precise pen presentation, dose, reimbursement status and launch timing vary by jurisdiction. The European Union and other markets may use different product presentations, reimbursement channels or administration schedules.
Geographic commercial performance depends on:
- National reimbursement decisions.
- Pharmacy versus hospital distribution.
- Local substitution rules.
- Biosimilar approval standards.
- Home-injection infrastructure.
- Pricing and reference-pricing systems.
The U.S. is strategically important because of the size of the IBD biologic market and the value of pharmacy-benefit access. Europe is more exposed to centralized procurement and biosimilar price competition.
What manufacturing barriers protect Entyvio?
Vedolizumab manufacturing requires mammalian-cell culture, purification, viral-clearance controls, analytical characterization and validated sterile filling. The pen adds device assembly, container-closure integrity, dose accuracy, human-factors validation and combination-product quality controls.
These manufacturing requirements are not absolute legal barriers. They can delay entry, increase capital needs and reduce the number of credible competitors. The most important practical constraint is the ability to manufacture consistent commercial-scale antibody while meeting device and cold-chain requirements.
Key Takeaways
- Entyvio Pen is a subcutaneous vedolizumab maintenance product designed to extend Entyvio’s commercial lifecycle.
- Takeda does not separately report pen revenue, so its financial trajectory must be inferred from total Entyvio sales and subcutaneous uptake.
- The pen’s primary value is patient convenience, home administration and retention of mature Entyvio patients.
- Entyvio’s 12-year U.S. biologic exclusivity period runs from the May 20, 2014 approval and reaches its principal endpoint in May 2026.
- Entyvio is not managed through the conventional Orange Book Paragraph IV framework.
- Biosimilar risk is highest after reference-product exclusivity, particularly if a competitor offers subcutaneous vedolizumab.
- Formulation, device, dosing and manufacturing patents can delay or complicate competition but are generally narrower than molecule-level protection.
- The key commercial question is whether pen conversion preserves net revenue or merely shifts patients from IV Entyvio to another Takeda presentation.
FAQs
Can Entyvio Pen be used without IV Entyvio induction?
The U.S. label positions Entyvio Pen for maintenance after at least two IV doses. It is not the standard stand-alone induction product under the FDA-approved regimen.
Does Entyvio Pen have a separate 12-year biologic exclusivity period?
No. The pen presentation does not ordinarily restart the reference product’s 12-year biologic data-exclusivity period.
Is Entyvio listed in the FDA Orange Book?
No. Entyvio is a biologic, so the FDA Purple Book is the relevant reference-product and biosimilar database.
Will an Entyvio biosimilar automatically be interchangeable with Entyvio Pen?
No. Interchangeability is a separate FDA designation. A biosimilar may be approved without being designated interchangeable, and the designation may depend on the product and application.
What will determine the value of Entyvio Pen after 2026?
The main variables are subcutaneous patient share, payer coverage, Takeda’s net pricing, the timing of vedolizumab biosimilars, patent settlements, and whether the pen retains patients who would otherwise switch to competing injectable IBD therapies.
References
-
U.S. Food and Drug Administration. (2014). FDA approves Entyvio to treat ulcerative colitis and Crohn’s disease. FDA.
-
U.S. Food and Drug Administration. (2023a). Entyvio prescribing information. Takeda Pharmaceuticals U.S.A., Inc.
-
U.S. Food and Drug Administration. (2023b). Entyvio Pen approval and labeling materials. FDA.
-
U.S. Food and Drug Administration. (2024a). Reference product exclusivity for biological products. FDA.
-
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. FDA.
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. Takeda.
-
Takeda Pharmaceutical Company Limited. (2023). Annual report 2023. Takeda.
